▶ 調査レポート

オキサリプラチンの世界市場:販売、インサイト

• 英文タイトル:Global Oxaliplatin Sale, Insights Market Research Report 2019-2025

Straits Researchが調査・発行した産業分析レポートです。オキサリプラチンの世界市場:販売、インサイト / Global Oxaliplatin Sale, Insights Market Research Report 2019-2025 / STR-DC032資料のイメージです。• レポートコード:STR-DC032
• 出版社/出版日:Straits Research / 2019年11月28日
• レポート形態:英文、PDF、150ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:製薬
• 販売価格(消費税別)
  Single User(1名様用、印刷不可)¥629,000 (USD4,250)▷ お問い合わせ
  Multi User(5名様用)¥836,200 (USD5,650)▷ お問い合わせ
  Enterprise Price(法人閲覧用)¥1,073,000 (USD7,250)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、オキサリプラチンの世界市場について調査・分析し、調査手法、市場概要、製品種類別(凍結乾燥粉末、水溶液)分析、用途別(III期結腸がんアジュバント療法、IV期結腸直腸がん治療、その他の用途)分析、エンドユーザー別(病院および診療所、研究所、その他のエンドユーザー)分析、地域別分析、企業概要などを含め次の構成でお届け致します。

・調査手法
・市場概要
・オキサリプラチンの世界市場:製品種類別(凍結乾燥粉末、水溶液)
・オキサリプラチンの世界市場:用途別(III期結腸がんアジュバント療法、IV期結腸直腸がん治療、その他の用途)
・オキサリプラチンの世界市場:エンドユーザー別(病院および診療所、研究所、その他のエンドユーザー)
・オキサリプラチンの世界市場:地域別
・企業概要

Global oxaliplatin market is expected to reach USD 548.6 million in 2028 from USD 981.99 million in 2018 at a negative CAGR of 5.7% during the forecast period 2019–2026

Oxaliplatin, an antineoplastic chemotherapy drug, is used to treat metastatic colorectal cancer. The drugs is administered in combination with fluorouracil and leucovorin.

In terms of the product lifecycle, the market for oxaliplatin has reached declining phase. The drug experienced introductory phase post its approval during 2002 – 2003, after which it was in the growth phase, during 2004 to 2009. In 2009, the market reached maturity, and was severely hit by the competition from generic drugs and other substitute therapies, resulting in the decline in the market size. Being in the declining phase, the market is expected to record a negative CAGR of -5.7% over the forecast period.

The parent market for oxaliplatin, i.e., colorectal cancer treatment market, is also declining as the number of screening programs for early disease diagnosis are rising globally. With this, if the disease is diagnosed at stage I or II, the tumors are removed by the surgery. Chemotherapy is preferred at the stage III and stage IV, owing to which, the scope of the treatment therapy is limited. Declining market can also be attributed to the growing preference for other therapies and rising number of new molecules under clinical studies. The effectiveness of the molecules currently under development, are found to exhibit potent results, compared to oxaliplatin. The side effects of the alternative therapies are also comparatively less. However, ongoing scenario might change in future, if oxaliplatin gets approval for other indications.

Key Findings
• Introduction of generics and emergence of alternative therapies, has resulted in the decline of the market size
• The preference for alternative therapies is increasing at a rapid rate owing to the better efficiency and less side effects as compared to oxaliplatin
• Rising screening programs for colorectal cancer has improved the diagnosis at earlier stages, wherein, the tumor is removed surgically, which reduces the chances of chemotherapy to treat the colorectal cancer
• The market dynamics might change in the future, if the approvals for other disease indications rises significantly
• In terms of the product type, lyophilized powder segment accounted for 53.9% in 2018 and it was valued at USD 529.62 million
• In the current scenario, the adoption of oxaliplatin to treat metastatic cancer is the highest in North America, owing to which it holds the largest share with 43.7%. The North America oxaliplatin market was valued at USD 428.9 million in 2018 and expected to reach 223.8 million by 2028, at a negative CAGR of -6.3%
• The rate of market decline will be lowest in the developing economies as the adoption of substitute therapies is the lowest in these regions. Moreover, the awareness of colorectal cancer screening programs is also less. At stage III or stage IV, the preferred treatment to treat colorectal cancer is chemotherapy. Thus, the market is declining at comparatively slow rates in the developing economies
• Asia Pacific was valued at 192.9 million in 2018 and expected to reach USD 126.7, at a negative CAGR of -4.2%

On the basis of formulations, the global oxaliplatin market is bifurcated into aqueous solution and lyophilized powder.

Lyophilized Powder Segment Offers Dominates the Market
Lyophilization is a freeze-drying process, which is performed to extend the shelf life of a product. The oxaliplatin lyophilized powder injection is prepared using a specific lyophilization process to increase the stability of drug, reduce the risk of side effects, and ensure a high degree of clinical usage. However, it is slightly expensive than aqueous solution. Global average selling price of 100 mg intravenous injection is around USD 84 – USD 500. Sanofi offers ELOXATIN in a lyophilized powder form..

Based on indication, the market is segmented into the adjuvant treatment of stage III colon cancer and treatment of stage IV colorectal cancer, and others.

Adjuvant Treatment of Stage III Colon Cancer Emerged as the Largest Segment in terms of Application
By application, the market is segmented into chemicals, wastewater management, oil and gas, food and beverages, pharmaceuticals, pulp and paper, and other industries.

Colorectal cancer is the second leading cause of cancer deaths in the U.S, and it costs around USD 8.4 billion a year, the Colon Cancer Coalition. In the recent past, the mortality rate of colorectal cancer has been reduced to a surprising level because of emerging advanced screening and diagnostic technologies and their rapid adoption. On the other hand, the survival rate with stage III and IV colorectal cancer has not improved much. Chemotherapy and targeted therapy are the most effective treatments for advanced stage of the disease. In Stage III, colon cancers oxaliplatin-based chemotherapy FOLFOX and XELOX are considered standard treatment and is widely adopted across worldwide. However, growing adoption of targeted therapies is limiting the use of oxaliplatin in developed economies.

Hospitals and Clinics Hold the Second Largest revenue Share in terms of the Market Size
Hospitals and clinics are leading the market as the majority of the patients frequently visit hospitals for diagnosis and treatment of cancer. According to the American Cancer Society, in 2014, cancer patients paid approximately USD 4,000 million out-of-pocket for cancer treatment, and roughly USD 87.8 million was spent alone in the U.S. on cancer-related healthcare. Furthermore, growing clinics and hospital infrastructure with added and improved services are expected to attract more patients towards hospitals & clinics for better treatment and care against cancer. Increasing number of oncologists and healthcare professionals, specializing in the diagnosis of cancer at an early stage and providing proper treatment is likely to escalate the hospital & clinics segment growth further

Asia Pacific offers lucrative opportunities for the market growth
In the last two decades, there has been dramatic rise in incidence of colorectal cancer and mortality in Asia. In China, colorectal cancer mortality in men accounts for around 5.5% of all cancers, the WHO. The region has diversified populations with varied disease prevalence, health beliefs, and healthcare infrastructure. The public is ill-informed about screening tests and benefits. Aging and geriatric populations are more prone to develop colorectal cancer and drive the demand for colorectal treatment therapies. In Asia Pacific, the number of geriatric populations is expected to reach 1.3 billion by 2050, the UN.
In most of the Asian countries, national healthcare systems and health insurance cover only a minority of people. So, access to healthcare facilities is limited in many rural areas and communities of low socioeconomic status. For instance, in China, over half of the population lives in rural areas, covering only about 10% under rural pension schemes. In India, the pension system for civil servants and private sector employees covers only about 14% of the workforce, the Asian Development Bank.

The prevalence of colon cancer is rising in many developing countries such as China, Japan, South Korea, and Singapore. Moreover, changing dietary habits, physical inactivity, smoking, and alcohol consumption are also contributing to rising CRC cases. In Japan, each year, around 125,000 people are diagnosed with CRC, and over 693,900 people die of CRC, the Japan Society of Clinical Oncology. To tackle this issue, in 2006, the Cancer Control Act was approved in Japan, and then the Basic Plan to Promote Cancer Control Program was subsequently developed, which clearly defined the goal of reducing mortality from cancer. Moreover, in Japan, screenings for gastric, colorectal, lung, breast, and cervical cancers have increased. In August 2019, Japan’s Ministry of Health, Labor, and Welfare (MHLH) has granted manufacturing and marketing approval for the OncoBEAM RAS CRC Kit. This will be used for molecular testing of advanced colorectal cancer patients. The availability of the OncoBEAM RAS CRC kit in Japan will reduce the need for invasive tissue biopsy and speed up the apt treatment therapy.

Prominent Players Active in the Market
Some of the key players in the global oxaliplatin market are Sanofi, Pfizer, Yakult Honsha, and Dr. Reddy’s laboratory.

レポート目次

TABLE OF CONTENTS
1 Research Methodology
1.1 Research Methodology
1.1.1 Research Scope and Assumptions
1.2 Data Sources
2 Oxaliplatin Market Overview
2.1 Global Oxaliplatin Market Size Status and Outlook (2013—2028)
2.1.1 Global Oxaliplatin Market Size Comparison by Region, USD Million, (2013-2028)
2.1.2 Global Oxaliplatin Market Size Comparison by Product Type, USD Million, (2013-2028)
2.1.3 Global Oxaliplatin Market Size Comparison by Application, USD Million, (2013-2028)
2.1.4 Global Oxaliplatin Market Size Comparison by End User, USD Million, (2013-2028)
2.2 Global Oxaliplatin Sales (K-Units) Status and Outlook (2013—2028)
2.3 Oxaliplatin Market Dynamics
2.3.1 Market Drivers
2.3.1.1 Increasing Prevalence of Colorectal Cancer
2.3.1.2 Advantageous Over Cisplatin
2.3.2 Market Restrain
2.3.2.1 Emergence of Alternative Drugs and Therapies
2.3.3 Market News (Mergers Acquisitions, and Expansion)
3 Oxaliplatin Market Segment Analysis by Player
3.1 Global Oxaliplatin Market Revenue and Market Share, by Player (2018)
4 Oxaliplatin Market Segment Analysis by Product Type
4.1 Global Oxaliplatin Market by Product Type
4.1.1 Lyophilized Powder
4.1.2 Aqueous Solutions
4.2 Global Oxaliplatin Revenue and Market Share by Product Type (2013–2018)
4.3 Global Oxaliplatin Sales and Market Share by Product Type (2013—2018)
5 Oxaliplatin Market Segment Analysis by Application
5.1 Global Oxaliplatin Market by Application
5.1.1 Adjuvant Treatment of Stage III Colon Cancer
5.1.2 Treatment of Stage IV Colorectal Cancer
5.1.3 Other Applications
5.2 Global Oxaliplatin Market Share by Application (2013 —2018)
5.3 Global Oxaliplatin Sales Market Share by Application (2013 —2018)
6 Oxaliplatin Market Segment Analysis by End User
6.1 Global Oxaliplatin Market by End User
6.1.1 Hospitals and Clinics
6.1.2 Research Institutes
6.1.3 Other End Users
6.2 Global Oxaliplatin Market Revenue and Share by End User, USD Million (2013—2018)
6.3 Global Oxaliplatin Market Sales and Share by End User, K-Units (2013—2018)
7 Oxaliplatin Market Segment Analysis by Region
7.1 Global Oxaliplatin Market Size by Region (2013—2028)
7.1.1 Global Oxaliplatin Market Revenue Share, by Region (2013—2018)
7.1.2 Global Oxaliplatin Market Sales, by Region (2013—2018)
7.2 North America
7.2.1 North America Market by Country
7.2.2 North America Oxaliplatin Market, by Product Type (2013—2018)
7.2.3 North America Oxaliplatin Market Share by Application (2013—2018)
7.2.4 North America Oxaliplatin Market Share by End User, (2013—2018)
7.2.5 United States
7.2.6 Canada
7.2.7 Mexico
7.3 Europe
7.3.1 Europe Market by Country
7.3.2 Europe Oxaliplatin Market, by Product Type (2013—2018)
7.3.3 Europe Oxaliplatin Market Share by Application (2013—2018)
7.3.4 Europe Oxaliplatin Market Share by End User, (2013—2018)
7.3.5 Germany
7.3.6 U.K.
7.3.7 France
7.3.8 Italy
7.3.9 Spain
7.3.10 Russia
7.3.11 Benelux
7.3.12 Rest of Europe
7.4 Asia-Pacific
7.4.1 Asia-Pacific Market by Country
7.4.2 Asia-Pacific Oxaliplatin Market, by Product Type (2013—2018)
7.4.3 Asia-Pacific Oxaliplatin Market Share by Application (2013—2018)
7.4.4 Asia-Pacific Oxaliplatin Market Share by End User, (2013—2018)
7.4.5 China
7.4.6 Japan
7.4.7 Korea
7.4.8 India
7.4.9 South East Asia
7.4.10 Australia
7.4.11 Rest of Asia Pacific
7.5 South America
7.5.1 South America Market by Country
7.5.2 South America Oxaliplatin Market, by Product Type (2013—2018)
7.5.3 South America Oxaliplatin Market Share by Application (2013—2018)
7.5.4 South America Oxaliplatin Market Share by End User, (2013—2018)
7.5.5 Brazil
7.5.6 Argentina
7.5.7 Colombia
7.5.8 Peru
7.5.9 Chile
7.5.10 Rest of South America
7.6 Middle East & Africa (MEA)
7.6.1 MEA Market by Country
7.6.2 MEA Oxaliplatin Market, by Product Type (2013—2018)
7.6.3 MEA Oxaliplatin Market Share by Application (2013—2018)
7.6.4 MEA Oxaliplatin Market Share by End User, (2013—2018)
7.6.5 South Africa
7.6.6 Egypt
7.6.7 Nigeria
7.6.8 Saudi Arabia
7.6.9 UAE
7.6.10 Rest of MEA
8 Profile of Leading Oxaliplatin Players
8.1 Sanofi
8.1.1 Company Description
8.1.1.1 Business Overview
8.1.2 Financial Performance
8.1.3 Product Portfolio
8.2 Yakult Honsha Co., Ltd.
8.2.1 Company Description
8.2.2 Business Overview
8.2.3 Financial Performance
8.2.4 Product Portfolio
8.3 Dr. Reddy’s Laboratories Ltd.
8.3.1 Company Description
8.3.2 Business Overview
8.3.3 Financial Performance
8.3.4 Product Portfolio
8.4 Sun Pharmaceutical Industries Ltd.
8.4.1 Company Description
8.4.2 Business Overview
8.4.3 Financial Performance
8.4.4 Product Portfolio
8.5 Teva Pharmaceutical Industries Ltd.
8.5.1 Company Description
8.5.2 Business Overview
8.5.3 Financial Performance
8.5.4 Product Portfolio
8.6 Fresenius Kabi AG
8.6.1 Company Description
8.6.2 Business Overview
8.6.3 Financial Performance
8.6.4 Product Portfolio
8.7 Pfizer Inc. (Hospira)
8.7.1 Company Description
8.7.2 Financial Performance
8.7.3 Product Portfolio
8.8 Mylan N.V.
8.8.1 Company Description
8.8.2 Business Overview
8.8.3 Financial Performance
8.8.4 Product Portfolio
8.9 Lunan Pharmaceutical Group
8.9.1 Company Description
8.9.2 Financial Performance
8.9.3 Product Portfolio
8.10 Shandong Luoxin Pharmaceutical Group Stock co., ltd.
8.10.1 Company Description
8.10.2 Financial Performance
8.10.3 Product Portfolio
8.11 Jiangsu Hengrui Medicine Co., Ltd.
8.11.1 Company Description
8.11.2 Financial Performance
8.11.3 Product Portfolio
8.12 Hainan Jinrui Pharmaceutical
8.12.1 Company Description
8.12.2 Business Strategy
8.12.3 Financial Performance
8.12.4 Product Portfolio
8.13 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
8.13.1 Company Description
8.13.2 Financial Performance
8.13.3 Product Portfolio
8.14 Yangtze River Pharmaceutical Group
8.14.1 Company Description
8.14.2 Financial Performance
8.14.3 Product Portfolio
8.15 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
8.15.1 Company Description
8.15.2 Financial Performance
8.15.3 Product Portfolio
8.16 Qilu Pharmaceutical Co., Ltd.
8.16.1 Company Description
8.16.2 Financial Performance
8.16.3 Product Portfolio
8.17 Lianyungang Jerui Pharmaceutical Co., Ltd.
8.17.1 Company Description
8.17.2 Financial Performance
8.17.3 Product Portfolio
8.18 Osei Kang Pharmaceutical Co., Ltd.
8.18.1 Company Description
8.18.2 Financial Performance
8.18.3 Product Portfolio
9 Upstream and Downstream Analysis of Oxaliplatin
9.1 Downstream of Oxaliplatin
9.1.1 Leading Distributors/Dealers of Oxaliplatin
10 Development Trend of Oxaliplatin (2019—2028)
10.1 Global Oxaliplatin Market Size (Revenue) Forecast USD Million, (2019—2028)
10.1.1 Global Oxaliplatin Market Size (Sales) Forecast, K-Units, (2019—2028)
10.2 Global Oxaliplatin Market Size (Revenue) Forecast, by Region (2019—2028)
10.3 Global Oxaliplatin Market Size (Sales) Forecast, by Region (2019—2028)
10.4 Global Oxaliplatin Market Size (Revenue) Forecast, by Type (2019—2028)
10.5 Global Oxaliplatin Market Size (Revenue) Forecast, by Application (2019—2028)
10.6 Global Oxaliplatin Market Size (Sales) Forecast, by Application (2019—2028)
10.7 Global Oxaliplatin Market Size (Revenue) Forecast, by End User (2019—2028)
10.8 Global Oxaliplatin Market Size (Sales) Forecast, by End User (2019—2028)
11 Conclusion

LIST OF TABLES

TABLE 1 Market News
TABLE 2 Global Oxaliplatin Revenue and Revenue Share by Player (2018)
TABLE 3 Global Oxaliplatin Revenue (USD Million) by Product Type, (2013—2018)
TABLE 4 Global Oxaliplatin Sales by Product Type, (K-Units), (2013—2018)
TABLE 5 Global Oxaliplatin revenue by Application, (USD Million), (2013—2018)
TABLE 6 Global Oxaliplatin Sales by Application, K-Units, (2013—2018)
TABLE 7 Global Oxaliplatin Revenue by End User, USD Million (2013—2018)
TABLE 8 Global Oxaliplatin Sales by End User, K-Units (2013—2018)
TABLE 9 Global Oxaliplatin Market Size by Region (USD MILLIONS), (2013-2028)
TABLE 10 Global Oxaliplatin Revenue Market Share by Region (2013—2018)
TABLE 11 Global Oxaliplatin Sales by Region, (K-Units) (2013—2018)
TABLE 12 North America Oxaliplatin Revenue by Country (usd million) (2013—2018)
TABLE 13 North America Oxaliplatin Revenue by Country, K-units (2013—2018)
TABLE 14 North America Oxaliplatin Market Revenue, by Product Type, USD MIllion, (2013—2018)
TABLE 15 North America Oxaliplatin Market Sales, by Product Type, K-Units, (2013—2018)
TABLE 16 North America Oxaliplatin Market RevenuE, by Application, USD Million, (2013—2018)
TABLE 17 North America Oxaliplatin Market Sales, by Application, K-Units, (2013—2018)
TABLE 18 North America Oxaliplatin Market RevenuE, by End User, USD Million, (2013—2018)
TABLE 19 North America Oxaliplatin Market Sales, by End User, K-Units, (2013—2018)
TABLE 20 Europe Oxaliplatin Revenue by Country (usd million) (2013—2018)
TABLE 21 Europe Oxaliplatin Revenue by Country, K-units (2013—2018)
TABLE 22 Europe Oxaliplatin Market Revenue, by Product Type, USD MIllion, (2013—2018)
TABLE 23 Europe Oxaliplatin Market Sales, by Product Type, K-Units, (2013—2018)
TABLE 24 Europe Oxaliplatin Market RevenuE, by Application, USD Million, (2013—2018)
TABLE 25 Europe Oxaliplatin Market Sales, by Application, K-Units, (2013—2018)
TABLE 26 Europe Oxaliplatin Market RevenuE, by End User, USD Million, (2013—2018)
TABLE 27 Europe Oxaliplatin Market Sales, by End User, K-Units, (2013—2018)
TABLE 28 Asia-Pacific Oxaliplatin Revenue by Country (usd million) (2013—2018)
TABLE 29 Asia-Pacific Oxaliplatin Revenue by Country, K-units (2013—2018)
TABLE 30 Asia-Pacific Oxaliplatin Market Revenue, by Product Type, USD MIllion, (2013—2018)
TABLE 31 Asia-Pacific Oxaliplatin Market Sales, by Product Type, K-Units, (2013—2018)
TABLE 32 Asia-Pacific Oxaliplatin Market RevenuE, by Application, USD Million, (2013—2018)
TABLE 33 Asia-Pacific Oxaliplatin Market Sales, by Application, K-Units, (2013—2018)
TABLE 34 Asia-Pacific Oxaliplatin Market RevenuE, by End User, USD Million, (2013—2018)
TABLE 35 Asia-Pacific Oxaliplatin Market Sales, by End User, K-Units, (2013—2018)
TABLE 36 South America Oxaliplatin Revenue by Country (usd million) (2013—2018)
TABLE 37 South America Oxaliplatin Revenue by Country, K-units (2013—2018)
TABLE 38 South America Oxaliplatin Market Revenue, by Product Type, USD MIllion, (2013—2018)
TABLE 39 South America Oxaliplatin Market Sales, by Product Type, K-Units, (2013—2018)
TABLE 40 South America Oxaliplatin Market RevenuE, by Application, USD Million, (2013—2018)
TABLE 41 South America Oxaliplatin Market Sales, by Application, K-Units, (2013—2018)
TABLE 42 South America Oxaliplatin Market RevenuE, by End User, USD Million, (2013—2018)
TABLE 43 South America Oxaliplatin Market Sales, by End User, K-Units, (2013—2018)
TABLE 44 MEA Oxaliplatin Revenue by Country (usd million) (2013—2018)
TABLE 45 MEA Oxaliplatin Revenue by Country, K-units (2013—2018)
TABLE 46 MEA Oxaliplatin Market Revenue, by Product Type, USD MIllion, (2013—2018)
TABLE 47 MEA Oxaliplatin Market Sales, by Product Type, K-Units, (2013—2018)
TABLE 48 MEA Oxaliplatin Market RevenuE, by Application, USD Million, (2013—2018)
TABLE 49 MEA Oxaliplatin Market Sales, by Application, K-Units, (2013—2018)
TABLE 50 MEA Oxaliplatin Market RevenuE, by End User, USD Million, (2013—2018)
TABLE 51 MEA Oxaliplatin Market Sales, by End User, K-Units, (2013—2018)
TABLE 52 Company Snapshot
TABLE 53 Financial Performance, 2016–2018 (USD MiLLION)
TABLE 54 Global Oxaliplatin Market Size (Revenue) and CAGR Forecast by Region, (USD Million) (2019-2028)
TABLE 55 Global Oxaliplatin Market Size (Sales) and CAGR Forecast by Region (K-Units), (2019-2028)
TABLE 56 Global Oxaliplatin Market Size (Revenue) Forecast, by Product Type, (USD Million), (2019—2028)
TABLE 57 Global Diaphragm Oxaliplatins Market Size (Revenue) Forecast, by Product Type, (USD Million), (2019—2028)
TABLE 58 Global Oxaliplatin Market Size (Revenue) Forecast, by Application, (USD Million) (2019—2028)
TABLE 59 Global Oxaliplatin Market Size (Sales) Forecast, by Application, (K-Units) (2019—2028)
TABLE 60 Global Oxaliplatin Market Size (Revenue) Forecast, by End User, (USD Million) (2019—2028)
TABLE 61 Global Oxaliplatin Market Size (Sales) Forecast, by End User, (K-Units) (2019—2028)


List of Figures


FIGURE 1 Global Oxaliplatin Revenue (USD Million) Status and Outlook (2013—2028)
FIGURE 2 Global Oxaliplatin Market Size Comparison by Region, USD Million, (2013-2028)
FIGURE 3 Global Oxaliplatin Market Size Comparison by Product Type, USD Million, (2013-2028)
FIGURE 4 Global Oxaliplatin Market Size Comparison by Application, USD Million, (2013-2028)
FIGURE 5 Global Oxaliplatin Market Size Comparison by End User, USD Million, (2013-2028)
FIGURE 6 Global Oxaliplatin Sales (K-Units) Status and Outlook (2013—2028)
FIGURE 7 Global Oxaliplatin Market revenue for lyophilized powder, USD Million, (2013—2019)
FIGURE 8 Global Oxaliplatin Market Sales for lyophilized powder, K-Units, (2013—2019)
FIGURE 9 Global Oxaliplatin Market revenue for Aqueous Solutions, USD Million, (2013—2019)
FIGURE 10 Global Oxaliplatin Market Sales for Aqueous Solutions, K-Units, (2013—2019)
FIGURE 11 Global Oxaliplatin Revenue for Adjuvant treatment of stage III colon cancer, USD Million, (2013—2019)
FIGURE 12 Global Oxaliplatin Revenue for Adjuvant treatment of stage III colon cancer, K-Units, (2013—2019)
FIGURE 13 Global Oxaliplatin Revenue for Treatment of Stage IV Colorectal Cancer, USD Million, (2013—2019)
FIGURE 14 Global Oxaliplatin Revenue for Treatment of Stage IV Colorectal Cancer, K-Units, (2013—2019)
FIGURE 15 Global Oxaliplatin Revenue for Other Applications, USD Million, (2013—2019)
FIGURE 16 Global Oxaliplatin Revenue for Other Applications, K-Units, (2013—2019)
FIGURE 17 Global Oxaliplatin MarkeT Revenue for Hospitals and Clinics, (USD Million), (2013—2019)
FIGURE 18 Global Oxaliplatin MarkeT Sales for Direct Channel, (K-Units), (2013—2019)
FIGURE 19 Global Oxaliplatin MarkeT Revenue for Research Institutes, (USD Million), (2013—2019)
FIGURE 20 Global Oxaliplatin MarkeT Sales for Research Institutes, (K-Units), (2013—2019)
FIGURE 21 Global Oxaliplatin MarkeT Revenue for Other End Users, (USD Million), (2013—2019)
FIGURE 22 Global Oxaliplatin MarkeT Sales for Other End Users, (K-Units), (2013—2019)
FIGURE 23 United States Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 24 United States Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 25 Canada Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 26 Canada Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 27 Mexico Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 28 Mexico Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 29 Germany Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 30 Germany Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 31 U.K. Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 32 U.K Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 33 France Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 34 France Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 35 Italy Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 36 Italy Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 37 Spain Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 38 Spain Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 39 Russia Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 40 Russia Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 41 Benelux Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 42 Benelux Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 43 Rest of Europe Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 44 Rest of Europe Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 45 China Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 46 China Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 47 Japan Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 48 Japan Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 49 Korea Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 50 Korea Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 51 India Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 52 India Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 53 South East Asia Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 54 South East Asia Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 55 Australia Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 56 Australia Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 57 Rest of Asia Pacific Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 58 Rest of Asia Pacific Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 59 Brazil Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 60 Brazil Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 61 Argentina Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 62 Argentina Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 63 Colombia Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 64 Colombia Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 65 Peru Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 66 Peru Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 67 Chile Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 68 Chile Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 69 Rest of South America Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 70 Rest of South America Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 71 South Africa Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 72 South Africa Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 73 Egypt Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 74 Egypt Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 75 Nigeria Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 76 Nigeria Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 77 Saudi Arabia Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 78 Saudi Arabia Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 79 UAE Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 80 UAE Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 81 Rest of MEA Oxaliplatin Market Revenue, (USD Million), (2013—2019)
FIGURE 82 Rest of MEA Oxaliplatin Market Sales, K-Units, (2013—2019)
FIGURE 83 Global Oxaliplatin Market Size (Revenue) Forecast USD Million, (2019—2028)
FIGURE 84 Global Oxaliplatin Market Size (Sales) Forecast, K-Units, (2019—2028)